Skip to main content
. 2015 Dec 9;7(3):3520–3532. doi: 10.18632/oncotarget.6513

Figure 2. BCL2 inhibitors increase the anti-lymphoma effect of RI-BPI in double-sensitive DLBCLs.

Figure 2

A. GI50 for ABT-737 and obatoclax (Y-axes) plotted against GI50 for RI-BPI (X-axes) in GCB-DLBCL cells. Dotted lines segregate resistant and sensitive cell lines. B. Effect of RI-BPI on pro-survival BCL2 family members in the double-sensitive GCB-DLBCL SU-DHL6, SC-1 and DoHH2 cells treated for 6 and 12 hours compared to their respective controls (full line). Dotted line represents 2-fold expression increase. C. RI-BPI effect on protein expression of BCL2, MCL1 and BCL-XL in SU-DHL6 cells. D. Isobologram analysis for ABT-737 (top) and obatoclax (bottom) in four double-sensitive GCB-DLBCL cell lines. Values bellow diagonal represent synergistic combinations.